The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

Biomarker Research

Volumn 4, Issue 1, 2016, Pages

  Reinholdt, Linn ^a   Laursen, Maria Bach ^a   Schmitz, Alexander ^a,b   Bødker, Julie Støve ^a,b   Jakobsen, Lasse Hjort ^a,b   Bøgsted, Martin ^a,b   Johnsen, Hans Erik ^a,b   Dybkaer, Karen ^a,b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

AMD3100; Anti CD20 antibody; CXCR4; CXCR4 antagonist; Diffuse large B cell lymphoma; DLBCL; Drug combination study; In vitro; Plerixafor; Rituximab

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; RITUXIMAB;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MTS ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84991022228     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/s40364-016-0067-2     Document Type: Article

References (61)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.
2. Friedberg JW. Diffuse Large B-Cell Lymphoma. Hematol Oncol Clin North Am. 2008;22:941-ix.
3. Coiffier B, Thieblemont C, Van Den NE, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-5.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
5. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91.
6. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2006;24:3121-7.
7. Cai Q, Westin J, Fu K, et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014;93:541-56.
8. Friedberg JW. Relapsed/Refractory Diffuse Large B-cell Lymphoma. Am Soc Hematol. 2011;498-505.
9. ReffME, Carner K, Chambers KS, et al. Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20. Blood. 1994;83:435-45.
10. O'Callaghan K, Lee L, Nguyen N, et al. Targeting CXCR4 with cellpenetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 2012;119:1717-25.
11. Hu Y, Gale M, Shields J, et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Leuk Lymphoma. 2012;53:130-8.
12. DiPersio JF, Uy GL, Yasothan U, et al. Plerixafor. Nat Rev Drug Discov. 2009;8: 105-6.
13. Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett. 2013;23:20-5.
14. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998;95:9448-53.
15. Zou Y-R, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595-9.
16. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761-7.
17. Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol. 2004;19:299-309.
18. Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;235:445-55.
19. Chen J, Xu-monette ZY, Deng L, et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015;6:5597-614.
20. Sehgal A, Keener C, Boynton AL, et al. CXCR-4, a Chemokine Receptor, Is Overexpressed in and Required for Proliferation of Glioblastoma Tumor Cells. J Surg Oncol. 1998;69:99-104.
21. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-6.
22. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367-75.
23. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341-51.
24. Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604-13.
25. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006;5:3113-21.
26. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005;106:1824-30.
27. Falgreen S, Laursen MB, Bødker JS, et al. Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition. BMC Bioinformatics. 2014;15:168.
28. Laursen MB, Falgreen S, Bødker JS, et al. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. Exp Hematol. 2014;42:927-38.
29. Chou T. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol Rev. 2006;58:621-81.
30. Nagajothi N, Matsui WH, Mukhina GL, et al. Enhanced Cytotoxicity of Rituximab Following Genetic and Biochemical Disruption of Glycosylphosphatidylinositol Anchored Proteins. Leuk Lymphoma. 2004;45:795-800.
31. Damås JK, Wæhre T, Yndestad A, et al. Stromal Cell-Derived Factor-1α in Unstable Angina: Potential Antiinflammatory and Matrix-Stabilizing Effects. Circulation. 2002;106:36-42.
32. Mazur G, Butrym A, Kryczek I, et al. Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor. PLoS One. 2014;9, e98194.
33. Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? Clin Cancer Res. 2011;17:2074-80.
34. Beider K, Ribakovsky E, Abraham M, et al. Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. Clin Cancer Res. 2013;19:3495-507.
35. Lee C-H, Kakinuma T, Wang J, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther. 2006;5:2592-9.
36. Juarez J, Bradstock KF, Gottlieb DJ, et al. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia. 2003;17:1294-300.
37. Welschinger R, Liedtke F, Basnett J, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2013;41: 293-302.
38. Andritsos L, Byrd JC, Jones JA, et al. Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Blood. 2010;116:Abstract 2450.
39. Lack NA, Green B, Dale DC, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther. 2005;77:427-36.
40. Kozin SV, Kamoun W, Huang Y, et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor re-growth after local irradiation. Cancer Res. 2010;70:5679-85.
41. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma. 2012;53:3-4.
42. Golay J, Introna M. Chemokines and antagonists in non-Hodgkin's lymphoma. Expert Opin Ther Targets. 2008;12:621-35.
43. Buchner M, Brantner P, Stickel N, et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol. 2010;151:167-78.
44. Kim H-Y, Hwang J-Y, Kim S-W, et al. The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro. Cancer Res Treat. 2010;42:225-34.
45. Fricker SP, Anastassov V, Cox J, et al. Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol. 2006;72:588-96.
46. Schols D, Esté JA, Henson G, et al. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4. Antiviral Res. 1997; 35:147-56.
47. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527:255-62.
48. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-47.
49. Lenz G. Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-cell Lymphoma and Its Therapeutic Implications. Cancers (Basel). 2015;7:811-22.
50. Es-haghi M, Soltanian S, Dehghani H. Perspective: Cooperation of Nanog, NF-kB, and CXCR4 in a regulatory network for directed migration of cancer stem cells. Tumor Biol. 2016;37:1559-65.
51. Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013;6: 1347-61.
52. Shin HC, Seo J, Kang BW, et al. Clinical significance of nuclear factor kB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Intern Med. 2014;29:785-92.
53. Huang C-Y, Lee C-Y, Chen M-Y, et al. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kB-dependent pathways. J Cell Physiol. 2009;221:204-12.
54. Tang C-H, Chuang J-Y, Fong Y-C, et al. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis. 2008;29:1483-92.
55. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol Nat Publ Group. 2012;25:145-56.
56. Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large BCell Lymphoma: Does Subtype Make a Difference in Therapy Selection? Am Soc Clin Oncol Educ B. 2015;35:e449-e457.
57. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319-31.
58. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590-603.
59. Luo J, Brendan MD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 2003;4:257-62.
60. Hatano K, Yamaguchi S, Nimura K, et al. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Mol Cancer Res. 2013;11:1088-100.
61. Mao W, Yi X, Qin J, et al. CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury. Int J Neurosci. 2014;124:281-90.